Early-stage opportunities for collaboration and/or licensing are currently being sought in the following therapeutic areas and areas of focus:
Oncology: Solid tumour of any organ, with the exception of the CNS (glioblastoma multiforme and other CNS tumours).
Inflammation: Including, but not limited to, rheumatoid arthritis, fibrosis, NASH, pulmonary hypertension, ALS, IBD and psoriasis.
Type of Target: Any target with a solid scientific rationale.
Type of Technology: Preferably small molecule, although a repurposed drug with commercial potential would be considered.
Development Stage: Lead optimisation, although if the target is novel, validated hit compounds would be considered.
Type of Collaboration: Sponsored research for 1-3 years, with an exclusive global license option.
Enquiries from University scientists / technology transfer offices, start-ups and SMEs, with opportunities within scope, are actively encouraged.